Predicting the effects of long-term medical treatment in acromegaly. At what cost? For what benefits?

Eur J Endocrinol. 1997 Apr;136(4):359-61. doi: 10.1530/eje.0.1360359.
No abstract available

Publication types

  • Comment

MeSH terms

  • Acromegaly / drug therapy*
  • Acromegaly / economics
  • Acromegaly / radiotherapy
  • Adenoma / diagnostic imaging
  • Adenoma / drug therapy
  • Adenoma / pathology
  • Cost-Benefit Analysis
  • Hormones / therapeutic use*
  • Humans
  • Octreotide / therapeutic use*
  • Peptides, Cyclic / therapeutic use*
  • Pituitary Neoplasms / diagnostic imaging
  • Pituitary Neoplasms / drug therapy
  • Pituitary Neoplasms / pathology
  • Predictive Value of Tests
  • Radionuclide Imaging / methods
  • Somatostatin / analogs & derivatives*
  • Somatostatin / therapeutic use

Substances

  • Hormones
  • Peptides, Cyclic
  • lanreotide
  • Somatostatin
  • Octreotide